Performance You Can Trust Page 4
Modal close icon

Prescribing information >

This is a promotional material fully funded by Bayer and is intended for UK healthcare professionals only. EYLEA (aflibercept) 8 mg is indicated in adults for the treatment of nAMD, visual impairment due to DMO and visual impairment due to macular oedema secondary to RVO (branch, central and hemiretinal RVO). Please refer to the licensed EYLEA 8 mg SmPC for the full licensed posology and the full summary of the safety profile. UK prescribing information and adverse event reporting can be accessed by clicking on the link above.

Request a copy: EYLEA (aflibercept) 8 mg Evidence Explorer

If you’d like to request a copy of any of the audits featured in the EYLEA 8 mg Evidence Explorer, please complete this form and select those of interest

(Please specify hospital name and NHS Trust)
(Please specify your hospital postcode)
Select studies

By ticking "I wish to subscribe to Bayer Communications" you authorise Bayer, as well as other Bayer AG Group companies, to directly deliver marketing/medical communications to you through e-mails or other electronic communications. They may contain information about services, products or events and may also contain promotional content. Our use of your data, including the analysis of such communications, is described in more detail at data privacy (http://go.bayer.com/PrivacyUK). You are free to revoke your consent at any time with future effect by clicking an unsubscribe link in any Bayer electronic communication.

DMO, diabetic macular oedema; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion; SmPC, Summary of Product Characteristics.